Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The ... Read more
Spherix announced that it has closed an exclusive option agreement to license PrAg-PAS, an anthrax-based potential therapy for ovarian cancer developed by scientists at the University of Maryland at Baltimore ... Read more
Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The ... Read more
Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients ... Read more
The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial ... Read more
PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be ... Read more
Pin It on Pinterest